- In January 2025, Terumo announces that Carter Blood care has become the first U.S. blood center to complete the transition to automated whole blood processing using Terumo's Reveos Automated Blood Processing System with Lumia Software. This innovative system automates the separation of whole blood into platelets, plasma, and red blood cells, improving the efficiency and accuracy of the process. By reducing the traditional 20+ steps to a single centrifugation cycle, the system enhances blood donation and processing, helping address critical platelet shortages. This milestone demonstrates Terumo’s commitment to advancing automation in the blood collection industry, with plans to expand the use of this technology in additional U.S. blood centers in the future
- In November 2024, Agilent Technologies has introduced a new organizational structure designed to enhance its market-focused strategy, with particular emphasis on the Life Sciences and Diagnostics Markets Group. This group will focus on advancing cell-based solutions in diagnostics, therapeutic development, and research, enabling Agilent to better serve the growing demand for cell biology and cellular analysis technologies. By re-aligning its business units, Agilent aims to accelerate innovation in areas such as single-cell analysis, genomics, and cell-based assays, supporting breakthroughs in cell therapies and drug discovery. This restructuring positions Agilent to lead in cell-focused technologies and further drive growth in life sciences
- In March 2024, Merck KGaA, Darmstadt, Germany, has announced an investment of more than €300 million to create a cutting-edge Life Science Research Center, with a strong focus on cell-based research. This new center will explore advanced technologies in cell biology, which play a key role in drug discovery, development, and production. The facility will serve as a hub for breakthrough research in cell therapies, regenerative medicine, and cellular diagnostics
- In October 2023, Thermo Fisher Scientific introduced the Gibco CTS Detachable Dynabeads with an active release mechanism. This innovative product allows for the controlled, active release of magnetic beads from target cells at any point during the process. It utilizes a competitive binding mechanism to detach the beads, providing greater flexibility in T-cell isolation, activation, and purification. This technology enables enhanced control over cell activation and ensures higher purity and yield of T-cells, which are crucial in cell therapies such as T-cell and gene therapies. It also shortens the manufacturing process and preserves early memory T-cell phenotypes, which are associated with higher efficacy in therapeutic treatments
- In July 2023, Lonza launched the TheraPRO CHO Media System, a new cell culture platform aimed at improving productivity and protein quality in therapeutic protein manufacturing. This system is designed to optimize the production of monoclonal antibodies and supports GS-CHO cell lines. It is scalable from cell line development to bioprocess manufacturing, offering significant performance improvements. The TheraPRO system delivers high viable cell concentrations and more than double the protein titer compared to existing solutions, helping reduce time-to-market. In addition, it simplifies media preparation and is supported by Lonza’s technical expertise for troubleshooting and regulatory guidance
